Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 5Meningioma 3Prostatic Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoid Tumor 2Neuroblastoma 1Neoplasms 1Glioma 1Ganglioneuroma 1Ganglioneuroblastoma 1Disease 1Carcinoma, Medullary 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Blood Specimen Collection 9Surveys and Questionnaires 6Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Prednisone 5Mammography 5Colonoscopy 5Biopsy 5Positron Emission Tomography Computed Tomography 4Magnetic Resonance Imaging 4Lenalidomide 4Biopsy, Fine-Needle 4pembrolizumab 3Tomography, X-Ray Computed 3Surgical Procedures, Operative 3Melphalan 3Liquid Biopsy 3Interviews as Topic 3Exercise 3Diagnostic Tests, Routine 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Urination 2Preoperative Exercise 2Positron-Emission Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × Ga(III)-DOTATOC × Clear all
NCT02359500 2017-05-03

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Icahn School of Medicine at Mount Sinai

Phase 1 Terminated
71 enrolled
EndocrineNET

Carcinoid Tumor, Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡